MagForce AG Announces Initiation Of Commercial Nanotherm Treatments For Brain Cancer At Vivantes Friedrichshain In Collaboration With Charité - Universitätsmedizin Berlin

BERLIN & CARSON CITY, Nev.--(BUSINESS WIRE)--MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that Vivantes Friedrichshain, Department of Neurosurgery has initiated Commercial NanoTherm(TM) Treatments for brain cancer in collaboration with Charité - Universitätsmedizin Berlin, Clinic for Radiation Therapy who is participating also in the ongoing post-marketing study.

NanoTherm(TM) Therapy is a brain tumor therapy that has CE certifications for the treatment of all brain cancers. It is used to enhance the effect of conventional radiation therapy. NanoTherm(TM) Therapy is applied by heating of the tumor from inside using nanoparticles, which are directly positioned neurosurgically into the tumor and are subsequently activated contactless to the patient by an alternating magnetic field. Preferentially, NanoTherm(TM) was successfully applied to the most malignant brain tumor which is Glioblastoma multiforme.

Dr. Ben Lipps, CEO of MagForce, stated, "We are pleased to have Vivantes Friedrichshain offer NanoTherm therapy to commercial patients in Berlin in conjunction with their excellent working relationship with the Clinic for Radiation Therapy of the Charité - Universitätsmedizin Berlin, which was the original development location of the NanoTherm Therapy. This cooperation between the Charité and Vivantes will provide the opportunity for patients from outside Germany to obtain this NanoTherm(TM) Therapy in Berlin, which is strategically close to Eastern European countries."

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com.

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Language:		English
Company:		MagForce AG
		Max-Planck-Straße 3
		12489 Berlin
		Germany
Phone:		+49 (0)30 308 380 0
Fax:		+49 (0)30 308 380 99
E-mail:		info@magforce.com
Internet:		www.magforce.com
ISIN:		DE000A0HGQF5
WKN:		A0HGQF
Listed:		Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart; Open Market (Entry Standard) in
		Frankfurt